Laboratory Billing Practices In Addiction Treatment Programs
A treatment center may collect urine specimens as part of a patient’s recovery plan. Months or years later, federal investigators can use those same specimens to build a criminal case around testing frequency, laboratory relationships, toxicology claims, and payments connected to patient referrals. What began as a clinical process can become the foundation for subpoenas, search warrants, employee interviews, and accusations that revenue shaped treatment decisions.
Claims data rarely tells the complete story, but it gives investigators a place to begin. Guidance from a knowledgeable Miami substance abuse treatment fraud lawyer can help identify where a billing pattern ends and evidence of individual knowledge, authority, and intent begins.
Claims Data Can Shape the Case Before Records Are Reviewed
Federal investigators can sort years of toxicology claims by patient, provider, date, code, and amount paid. High testing volume or similar billing across a large patient population may create the appearance of a coordinated practice before agents examine a single chart.
Data patterns can drive subpoenas for treatment notes, laboratory requisitions, contracts, payroll records, and electronic communications. Employees may then face questions about protocols created long before anyone anticipated criminal scrutiny.
Statistics cannot explain why a particular test was ordered. Claims data also leaves out suspected relapse, medication concerns, behavioral changes, and information disclosed during treatment.
Repeated Testing Can Be Recast as a Revenue Strategy
Urine drug testing can help a clinician evaluate substance use, confirm medication adherence, or respond to signs of relapse. Investigators will still ask why a particular patient was tested on a particular date.
Repeated claims draw closer scrutiny when results remain unchanged or treatment records show little movement between visits. Fixed schedules can appear disconnected from clinical judgment when progress notes offer no patient-specific explanation.
Missed appointments, behavioral changes, new prescriptions, or unexpected results may support continued testing. Records created during treatment carry more weight than explanations developed after an audit begins.
Broad Toxicology Panels Can Increase the Exposure
Definitive testing can identify specific drugs or metabolites that a presumptive screen cannot isolate. Using the same expansive panel across nearly every patient creates a different concern.
Tests for substances unrelated to a person’s prescriptions, treatment history, or suspected use can support an accusation that reimbursement influenced the order. Repeated generic language across charts gives prosecutors more room to argue that the panel came before the clinical reason.
Timing can also affect how the order is viewed. Definitive testing after an unexpected result may reflect a targeted decision. Automatic confirmation before anyone reviews the initial screen can appear to be part of a predetermined billing process.
Electronic Orders May Hide Who Controlled the Testing
A physician’s name on a laboratory order can place that physician at the center of the investigation. A signature or credential, however, may reveal little about how the test was selected.
Treatment programs may rely on standing protocols, delegated ordering functions, electronic templates, and laboratory interfaces. Staff members can enter orders through credentials assigned to a medical director, while an outside laboratory may help configure panels used throughout the facility.
Audit trails can establish who accessed the chart, selected the test, changed the order, or transmitted the claim. Those records may separate clinical judgment from decisions made elsewhere under the physician’s credentials.
Laboratory Relationships Can Expand the Investigation
Payments between a treatment program and a toxicology laboratory can move the inquiry beyond medical necessity. Ownership interests, marketing arrangements, consulting contracts, and compensation connected to laboratory business may all receive scrutiny.
The Eliminating Kickbacks in Recovery Act, 18 U.S.C. § 220, prohibits certain knowing and willful remuneration connected to referrals to recovery homes, clinical treatment facilities, and laboratories. Its reach is not limited to services paid by federal health care programs.
Referral volume can change how an otherwise ordinary contract appears. Compensation that rises with specimens or laboratory collections may draw attention when the stated services are difficult to verify.
Separate Decision-Makers Can Be Compressed Into One Theory
Federal health care fraud under 18 U.S.C. § 1347 requires a knowing and willful scheme to defraud a health care benefit program or obtain its money through false or fraudulent representations. High billing volume and weak documentation may create suspicion without establishing what each person knew.
Different people can control different parts of a treatment operation. Clinicians assess patients, staff members enter orders, laboratories process specimens, and billing companies submit claims. Executives may negotiate contracts without participating in clinical care.
Prosecutors may compress those functions into one account of how the program operated. Access records, assigned responsibilities, communications, and payment authority can restore the divisions hidden by that account.
The Clinical Timeline Can Challenge the Billing Narrative
Claims analysis organizes testing into dates, codes, and payments. It cannot reconstruct the circumstances that brought a patient into the office or changed the course of treatment.
A close review may show that testing followed missed sessions, altered behavior, suspected diversion, medication changes, or inconsistent results. Later decisions can also reveal how the findings affected care.
Records connecting a test to a change in supervision, medication, counseling, or the recovery plan can weaken an accusation based primarily on volume and cost.
Individual Responsibility Must Be Established Through the Record
Substance abuse treatment fraud investigations can place physicians, medical directors, program owners, marketers, and billing personnel in conflict. Each participant may have controlled a different part of the operation.
Contracts, access logs, emails, compensation records, and ordering histories can establish who approved the testing structure, controlled the laboratory relationship, and understood the claims process. Working with an experienced Miami substance abuse treatment fraud lawyer can help separate individual conduct from decisions made elsewhere within the program.
Contact The Baez Law Firm
If you are facing a federal investigation involving a substance abuse treatment program, early assumptions about the operation can quickly shape the case. Records and statements gathered at the outset may influence how prosecutors assign responsibility and interpret legitimate treatment decisions.
At The Baez Law Firm, we represent physicians, medical directors, treatment professionals, and program operators accused of substance abuse treatment fraud. Contact our firm today to speak with an experienced Miami substance abuse treatment fraud lawyer and learn how we can prevent billing patterns from being mistaken for criminal intent.
Source:
- 18 U.S.C. § 220 – Illegal Remunerations for Referrals to Recovery Homes, Clinical Treatment Facilities, and Laboratories
uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title18-section220 - 18 U.S.C. § 1347 – Health Care Fraud
uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title18-section1347 - Centers for Medicare & Medicaid Services – Urine Drug Testing, Local Coverage Determination L34645
cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=34645 - Centers for Medicare & Medicaid Services – Billing and Coding for Urine Drug Testing, Article A56915
cms.gov/medicare-coverage-database/view/article.aspx?articleId=56915
